Upon effectiveness of the merger with Novartis AG (NYSE: NVS), Avidity Biosciences Inc. (NASDAQ: RNA) is expected to be suspended from trading on Nasdaq on March 2, 2026. Prior to the merger, Avidity Biosciences Inc. will spin-off Atrium Therapeutics, Inc into a separate publicly traded company, using the symbol RNA upon listing on Nasdaq, which is expected to occur on February 27, 2026, following shareholder approval of the spin off on February 26, 2026. In anticipation of the symbol reassignment of RNA to Atrium Therapeutics, Inc. on February 27, 2026, Avidity Biosciences, Inc. (RNA) will undergo a symbol change from RNA to RNAM effective February 26, 2026.

Nasdaq requests that market data redistributors note this is a symbol reuse and history should carry NOT over from current RNA to new RNA (once listed). The history from current RNA should carry over to RNAM effective February 26, 2026.